UK braces for growth in demand for LDR (low dose rate) prostate brachytherapy for prostate cancer
This article was originally published in Clinica
Executive Summary
New UK National Health Service guidelines supporting low dose rate (LDR) brachytherapy for localised prostate cancer appear to have caught the Department of Health by surprise, obliging it to launch a consultation on how best to ensure services can meet an expected significant rise in demand for the procedure.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.